{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"}],"units":"Participants"}],"description":"Number of participants without progressive disease at the end of the study period, using the definitions for complete response, partial response and progressive disease from the International Myeloma Working Group .","groups":[{"description":"busulfan: IV busulfan 0.8 mg/kg every 6 hours x 16 doses\n\ncyclophosphamide: IV cyclophosphamide 60 mg/kg over 4 hours x 2 days\n\nautologous hematopoietic stem cell transplantation: infusion of autologous hematopoietic stem cells of at least 2.0 x 106 CD34+ cells/kg on day 0","id":"OG000","title":"Busulfan Treatment"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"at 6 months","title":"Relapse-free Survival","type":"PRIMARY","unitOfMeasure":"participants"}